Cargando…

How shall we treat locally advanced triple negative breast cancer?

Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate...

Descripción completa

Detalles Bibliográficos
Autores principales: Luz, Paulo, Dias, David, Fortuna, Ana, Bretes, Luis, Gosalbez, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411516/
https://www.ncbi.nlm.nih.gov/pubmed/32802311
http://dx.doi.org/10.12688/f1000research.20509.2
_version_ 1783568397495173120
author Luz, Paulo
Dias, David
Fortuna, Ana
Bretes, Luis
Gosalbez, Beatriz
author_facet Luz, Paulo
Dias, David
Fortuna, Ana
Bretes, Luis
Gosalbez, Beatriz
author_sort Luz, Paulo
collection PubMed
description Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC
format Online
Article
Text
id pubmed-7411516
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-74115162020-08-13 How shall we treat locally advanced triple negative breast cancer? Luz, Paulo Dias, David Fortuna, Ana Bretes, Luis Gosalbez, Beatriz F1000Res Opinion Article Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC F1000 Research Limited 2020-05-04 /pmc/articles/PMC7411516/ /pubmed/32802311 http://dx.doi.org/10.12688/f1000research.20509.2 Text en Copyright: © 2020 Luz P et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Opinion Article
Luz, Paulo
Dias, David
Fortuna, Ana
Bretes, Luis
Gosalbez, Beatriz
How shall we treat locally advanced triple negative breast cancer?
title How shall we treat locally advanced triple negative breast cancer?
title_full How shall we treat locally advanced triple negative breast cancer?
title_fullStr How shall we treat locally advanced triple negative breast cancer?
title_full_unstemmed How shall we treat locally advanced triple negative breast cancer?
title_short How shall we treat locally advanced triple negative breast cancer?
title_sort how shall we treat locally advanced triple negative breast cancer?
topic Opinion Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411516/
https://www.ncbi.nlm.nih.gov/pubmed/32802311
http://dx.doi.org/10.12688/f1000research.20509.2
work_keys_str_mv AT luzpaulo howshallwetreatlocallyadvancedtriplenegativebreastcancer
AT diasdavid howshallwetreatlocallyadvancedtriplenegativebreastcancer
AT fortunaana howshallwetreatlocallyadvancedtriplenegativebreastcancer
AT bretesluis howshallwetreatlocallyadvancedtriplenegativebreastcancer
AT gosalbezbeatriz howshallwetreatlocallyadvancedtriplenegativebreastcancer